Nov 29, 2021 / 04:00PM GMT
Jacob K. Johnson - Stephens Inc., Research Division - Analyst
All right. Good morning, everybody. Welcome to day 1 of the Stephens Investment Conference. I'm Jacob Johnson, the life science tools and diagnostics analyst here at Stephens. I'm not sure there's a better way to kick it off. And with the team from Catalent today, we have CFO, Tom Castellano; and Paul Surdez from Investor Relations. Tom, Paul, thank you for joining. I'll let you kick it off with some opening comments, and then we'll launch into Q&A.
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Yes. Great, Jacob. Thanks. Happy to be here. I appreciate the opportunity as always here.
Just a couple of quick comments on Catalent. We're coming off of a really strong start to fiscal '22 with our strongest first quarter we've ever had here, which, by the way, is our seasonally lightest quarter. We saw 23% revenue growth organically, 52% adjusted EBITDA growth. And Biologics continues to be the main contributor, but we are seeing a recovery within our SOT and OSD businesses as well
Catalent Inc at Stephens Investment Conference (Virtual) Transcript
Nov 29, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers